Krishnan (Nandu) Nandabalan Ph.D.

President and CEO

Over the past decade, Dr. Nandabalan has pioneered the application of big data analytics, artificial intelligence (AI), and machine learning (ML) to monitor emerging healthcare innovation through the assimilation and query of large data sets. He successfully led the spinout of BioXcel Therapeutics (NASDAQ: BTAI), and InveniAI, from parent company BioXcel LLC. InveniAI has successfully created an AI- and ML-powered platform that monitors drug targets, drugs, and healthcare products and technologies. Dr. Nandabalan is a serial entrepreneur with over two decades of experience in the pharmaceutical and biotechnology industries, including R&D, operations, and business development. He has extensive experience in M&A and in- and out-licensing. He has completed deals with key industry players such as AstraZeneca, Biogen, BMS, Daiichi Sankyo, GSK, J&J, Kyowa Kirin, Merck KGaA, Millennium Pharmaceuticals, Novartis, Organon, Otsuka, Pfizer, Pharmacia, Shionogi, and Takeda, among others.

He served as VP of Corporate Development at Genaissance Pharmaceuticals, a trailblazer in pharmacogenomics and its widespread cceptance. Before this, he was Group Leader of the Functional Genomics Group at CuraGen Corp. He has 12 issued patents and published in leading journals such as Cell and Science. He holds a Ph.D. in Biochemistry and Molecular Biology from the Indian Institute of Science, India, and was a Post-Doctoral Fellow at Yale University, Connecticut.

Aman Kant

Chief Business Officer

Mr. Kant is a passionate leader with over 15 years of experience driving organizational strategy, productivity and efficiency, P&L, competitive strategy, and building and leading global, cross-functional teams. Mr. Kant is responsible for managing external partners including IR/PR, marketing agencies for branding and positioning, and designing and implementing best practices and strategy to drive value for corporate stakeholders via industry collaborations. His extensive knowledge of competitive strategy, deal-making, and alliance management has led to the consummation of more than two-dozen significant transactions across the US, EU and Asian markets. He is highly focused and adept at delivering value to partners through technology solutions with a depth and breadth of knowledge spanning all major therapeutic areas and modalities impacting biopharma innovation. Mr. Kant has expert knowledge across adjacencies such as consumer healthcare, vaccines, animal therapeutics, and nutrition. He also played a key role raising both private and public capital for BioXcel LLC and its subsidiaries.

Prior to joining InveniAI, Mr. Kant played a significant role in the parent Company, BioXcel LLC, where he led the assessment and negotiation of numerous collaborations that expanded and strengthened the value proposition of big data analytics and AI tools across the pharmaceutical R&D value chain. Mr. Kant has forged strong relationships with key opinion leaders and industry executives with a focus on bringing people together to ultimately impact human health and wellness. Mr. Kant holds a B.Tech in Biotechnology.

Madan Anant, Ph.D.

Chief Scientific Officer

Dr. Anant is a target discovery professional with over 20 years of experience in diverse biomedical research. He has expertise in conducting scientific due diligence and designing and developing proof-of-concept programs in all major therapeutic areas As a scientist with a proven track record in target identification and validation and a crucial inquisitiveness, he has provided valuable biological insights and recommendations on novel target discovery programs in a number of major therapeutic areas. In his previous roles at CuraGen, Genelogic, and Genaissance Pharmaceuticals, as Program Lead and Director of Scientific Alliances, he led multiple biotech and pharmaceutical collaborations and provided actionable scientific insights on target selection to their target discovery teams. He has been instrumental in prioritizing R&D initiatives for biologics, small molecules, biomarkers, and technologies based on feasibility of development, clinical impact, and their commercial potential. He has a bachelor’s and master’s degree in Veterinary sciences, a Ph.D. in Microbiology and Cell Biology from the Indian Institute of Science, India, and Post-doctoral experience from Yale University.

Sheryl Bauer, Ph.D.

Senior Vice President, Operations, Strategy & Alliance Management

Sheryl is an operational leader with 25 years of experience in drug development, registration, and commercialization. She has expertise in many aspects of the biopharma industry including strategic planning, business operations, program and alliance management, drug production, clinical development, regulatory affairs, and quality assurance. Most recently in leadership roles at small and growing biotechnology companies Angion Biomedica and Akcea Therapeutics, Sheryl built strong quality and program and alliance management functions, leading program teams through Phase 1, 2, and 3 studies, registrational drug submissions, and drug approval and launch in Europe. During almost twelve years at Biogen, her roles spanned Japan strategic operations for R&D, global planning and operations for development sciences, and manufacturing sciences and planning within Pharmaceutical Operations and & Technology (PO&T). Sheryl's experience includes many disease areas, indications, drug modalities, and clinical and nonclinical approaches. While at Biogen and Akcea, and earlier as a research scientist and group leader at Wyeth Vaccines, Sheryl has had direct or supportive involvement in the development, registration, and/or commercial maintenance of ~a dozen licensed therapeutics and vaccines. She has B.S. and Ph.D. degrees in Chemical Engineering and completed the program for leadership development at Harvard Business School.

Michael Aiello, CPA

Vice President, Finance and Accounting

Having worked for several life-science companies, he brings diverse financial management experience in executing financial plans with consistent success in improving performance and company value. He has a history of starting, growing, and improving profitability in small and medium-sized companies while positioning them for the next phase of growth. Mr Aiello began his career in public accounting with KPMG followed by financial leadership roles, most notably as CFO of Precision X-Ray, a manufacturer of biological lab equipment, where he helped achieve double digit revenue growth resulting in a substantial increase in enterprise value. As Corporate Controller of SurgiQuest, a medical device start-up, he helped to lead a $265 million acquisition of SurgiQuest after an initial public offering. Prior to that, he served in several financial leadership roles working for both private and publicly traded companies where he honed his skillset as a financial leader. He earned his degree in Accounting from Quinnipiac University, Hamden, Connecticut. Michael is a Certified Public Accountant.

Anita Ganjoo, Ph.D.

Vice President, External Communications

Dr. Ganjoo is a marketing and corporate communications specialist with 10 years of experience. She has created, developed, and managed content for all corporate functions, including marketing, media, and investor relations, as well as developing and implementing corporate communications goals and strategies. She has primarily worked for start-ups that have grown through to IPO. She previously worked for BioXcel LLC, where she headed their corporate communications, and prior to this, she worked in scientific communications at Genaissance Pharmaceuticals, a trailblazer in pharmacogenomics and personalized medicine. She completed two Post-Doctoral Fellowships at Lund University, Sweden, and at The University of Reading, UK, where she also received her Ph.D. in Biotechnology. She is the author of numerous publications and a book chapter on the applications of aqueous two-phase systems in protein purification.

Mansi Joshi

Vice President, Business Development & Alliances

Mansi is a dynamic and seasoned professional with over 12 years of experience in the biopharma industry, specializing in business development and alliance management. She is recognized for her ability to forge and manage industry collaborations, driving successful outcomes in highly competitive markets. Mansi's strategic insights have been instrumental in shaping and executing AI-driven drug discovery deals for InveniAI, where she has made significant contributions across the US, EU, and Japan. Her diverse skill set and extensive knowledge span various sectors, including pharma, consumer health, vaccines, and animal health. Mansi's professional journey includes pivotal roles at organizations such as LG Life Sciences, where she spearheaded product out-licensing, in-licensing, and co-marketing initiatives and developed product launch strategies. With a background in both biotechnology and marketing, Mansi brings a unique blend of scientific expertise and strategic acumen to her roles. She holds a Master's in Biotechnology from St. Xavier's College, India, complemented by an MBA in Marketing from the Institute of Management Technology, India.

Govindan Vijayadamodar, Ph.D., MBA

Vice President, AI & Analytics

Dr. Vijayadamodar is a passionate data science professional with over 27 years of experience in bioinformatics, computational biology, machine learning, experimental design, statistics, and data engineering. He has dedicated his career working at the forefront of applying technology-enabled solutions to expedite drug discovery and development for areas of high unmet medical need. He previously worked at CuraGen, 454 Life Sciences, Roche Diagnostics, and Clinical Data, where he applied his diverse cross-disciplinary expertise and creativity to drive drug discovery innovation logically, rapidly, and efficiently. He is a strong leader with project management experience involving cross-functional teams. He holds a Ph.D. from the Indian Institute of Science, India, and completed Postdoctoral fellowships at Tel Aviv University, Israel, and Boston University, MA. In addition, he holds an MBA from the University of New Haven, CT.

Sanatan Upmanyu

Head of Data Sciences and Switzerland Site Head

Mr. Upmanyu is a seasoned data scientist with a background in molecular biology and more than 15 years of experience executing data-driven solutions to increase the efficiency and accuracy of scientific data processing and assimilation. He specializes in utilizing statistical, mathematical, and machine learning models with a business strategy perspective, to build algorithms necessary to pose the right questions to find the most appropriate solutions, in the pursuit of advancing global healthcare and life science innovation. Mr. Upmanyu has maintained a deep understanding of the domain and his work has been the basis of several scientific projects, patents, and research publications. He has taken the initiative and conducted exploratory data analyses and experimental designs that have provided a deeper understanding of the trends and behaviors within these markets to ultimately customize the most suitable strategies and innovative solutions. Mr. Upmanyu is also responsible for managing processes, design, research, development, and delivery of our AlphaMeld® Platform and ChatAlphaMeld. He was also responsible for conceptualization, building, and executing innovative solutions across the life cycle of drug discovery and development by leveraging Data Science and the power of Artificial Intelligence. He is also responsible for managing and growing our business in the EU from Basel, Switzerland. Mr. Upmanyu holds a B.Tech in Biotechnology.